Born of frustration: the emergence of Camelina sativa as a platform for lipid biotechnology.

Abstract

The emerging crop Camelina sativa (L.) Crantz (camelina) is a Brassicaceae oilseed with a rapidly growing reputation for the deployment of advanced lipid biotechnology and metabolic engineering. Camelina is recognised by agronomists for its traits including yield, oil/protein content, drought tolerance, limited input requirements, plasticity and resilience. Its utility as a platform for metabolic engineering was then quickly recognised, and biotechnologists have benefited from its short life cycle and facile genetic transformation, producing numerous transgenic interventions to modify seed lipid content and generate novel products. The desire to work with a plant that is both a model and crop has driven the expansion of research resources for camelina, including increased availability of genome and other “-omics” data sets. Collectively the expansion of these resources has established camelina as an ideal plant to study the regulation of lipid metabolism and genetic improvement. Furthermore, the unique characteristics of camelina enables the design-build-test-learn cycle to be transitioned from the controlled environment to the field. Complex metabolic engineering to synthesize and accumulate high levels of novel fatty acids and modified oils in seeds, can be deployed, tested and undergo rounds of iteration in agronomically relevant environments. Engineered camelina oils are now increasingly being developed and used to sustainably supply, improved nutrition, feed, biofuels and fossil fuel replacements for high-value chemical products. In this review, we provide a summary of seed fatty acid synthesis and oil assembly in camelina, highlighting how discovery research in camelina supports the advance of metabolic engineering towards the predictive manipulation of metabolism to produce desirable bio-based products. Further examples of innovation in camelina seed lipid engineering and crop improvement are then provided, describing how technologies (e.g., genetic modification (GM), gene editing (GE), RNAi, alongside GM and GE stacking) can be applied to produce new products and denude undesirable traits. Focusing on the production of long chain polyunsaturated omega-3 fatty acids in camelina, we describe how lipid biotechnology can transition from discovery to a commercial prototype. The prospects to produce structured triacylglycerol with fatty acids in specified stereospecific positions are also discussed, alongside the future outlook for the agronomic uptake of camelina lipid biotechnology.